Search Results

Containing any of the words

Only of the type

A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP). Drug Clinical Trial

A H3N2 Avictoria 800 2024 CVR 289,A H1N1 A Georgia 12 2022 CVR 167,B Victoria Lineage B Singapore WUH4618 2021 New SFDA Drug Approvals

A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biological meningococcal conjugate vaccine, MenACWYTT (GSK134612) in healthy infants, given on a 3+1 primary and booster (2, 4, 6 and 15-18 months of age), a 1+1 primary and booster (6 and 15-18 months of age), or as a single dose at 15-18 months of age Drug Clinical Trial

A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biological meningococcal conjugate vaccine, MenACWYTT (GSK134612) in healthy infants, given on a 3+1 primary and booster (2, 4, 6 and 15-18 months of age), a 1+1 primary and booster (6 and 15-18 months of age), or as a single dose at 15-18 months of age Drug Clinical Trial

Rules and Protocols are Applied in Food Facilities in Cases of Food Poisoning or Suspected Cases Regulations

Linagliptin, Metformin HCL New SFDA Drug Approvals

Linagliptin, Metformin HCL New SFDA Drug Approvals

Linagliptin, Metformin HCL New SFDA Drug Approvals

SFDA Approves Marketing Authorization for Advanced Brain-Stimulation Medical Device for Parkinson's Disease News

GSR DEFINE Clinical Investigation Plan Clinical Trial